Segment Information (Tables)

6 Months Ended

Jun. 30, 2025

Reconciliation of revenue from segments to consolidated

The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
(In millions)	2025		2024		2025		2024
Total revenue	$	2,645.5	$	2,464.9	$	5,076.5	$	4,755.4
Less cost and expense:
Cost of sales, excluding amortization and impairment of acquired intangible assets:
Product cost of sales	415.0		358.4		877.2		736.1
Royalty cost of sales	190.0		187.6		357.1		352.1
Research and development:
Research and discovery	46.6		45.7		90.9		93.3
Early stage programs	51.9		66.6		124.3		150.7
Late stage programs	44.6		46.7		94.0		79.3
Marketed products	87.7		170.0		177.2		288.1
Other research and development costs(1)	168.2		176.4		346.7		339.4
Acquired in-process research and development, upfront and milestone expense	46.6		8.5		247.3		16.0
Selling, general and administrative	583.8		553.8		1,156.3		1,135.3
Other segment expense(2)	376.3		267.6		730.2		588.1
Net Income attributable to Biogen Inc.	$	634.8	$	583.6	$	875.3	$	977.0

(1) Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.

(2) Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; gain on sale of priority review voucher, net; other (income) expense, net; and income tax (benefit) expense